Linagliptin Krka

Linagliptin, the active ingredient in Linagliptin Krka, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used as part of a comprehensive diabetes treatment plan that may include diet, exercise and other glucose‑lowering agents.

GNH USA supplies Linagliptin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for healthcare providers.

Linagliptin is a DPP‑4 inhibitor used in the management of disorders related to glucose metabolism. - Type 2 diabetes mellitus (monotherapy): reduces fasting and post‑prandial glucose levels, improving overall glycemic control. - Type 2 diabetes mellitus (combination therapy): used together with metformin or other oral agents to achieve target HbA1c. - Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise interventions to maintain blood glucose within target range.

Linagliptin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as nasal congestion or sore throat. - Headache: transient mild to moderate pain. - Gastrointestinal discomfort: includes nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain possibly radiating to the back. - Severe hypersensitivity reactions: including angioedema or anaphylaxis. - Hepatic enzyme elevation: significant increase in ALT/AST levels.

When prescribing Linagliptin, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function before initiation and monitor periodically. - Hepatic dysfunction: use with caution in patients with liver disease and monitor liver enzymes. - Cardiovascular disease: evaluate risk as patients with existing heart conditions may need closer observation. - Concomitant medications: review for potential drug interactions, especially with strong CYP inhibitors. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Linagliptin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin plasma concentrations, raising risk of adverse effects. - Combination with insulin secretagogues: can cause excessive hypoglycemia when used together.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance, requiring dose adjustment. - Anticoagulants: monitor INR or clotting parameters as glycemic changes can influence anticoagulation. - Rifampicin: may reduce linagliptin exposure, potentially diminishing glucose‑lowering effect.